论文部分内容阅读
为观察膀胱局部免疫活性细胞对BCG的反应,作者于灌药前后作膀胱壁活体组织检查,病人包括pTa——PT_1期1～3级的表浅性膀胱肿瘤。肿瘤电切后用YAG激光凝固肿瘤基底部,术后7～10天开始灌注,BCG120mg每周一次,连续6周,以后每3个月一次,持续1年。每3个月进行一次膀胱镜和脱落细胞学检查。分别于灌前、第6次结束后的24小时内和每3个月进行一次活检,持续1年。在手术疤痕边缘和正常粘膜处取材,标本立即放于液氮中,-70℃保存。制备冰冻切片,按Cordell方法染色。用单克隆和多隆抗体标记后进行检测。对肌层,粘膜下和上皮层进行镜检,每个病人至少计数3个显微镜视野的浸润细胞类型(Th/Ti,Ts/Tc、白细胞介素-2
In order to observe the response of local immunocompetent cells to BCG, the authors performed biopsy of the bladder wall before and after the administration of the drug. The patients included pTA--superficial bladder tumors of stage 1-3 of PT-1 stage. After tumor electrocution, the tumor basement was solidified with YAG laser and perfusion was started 7-10 days postoperatively. BCG 120 mg once a week for 6 consecutive weeks and once every 3 months for 1 year. Cystoscopy and exfoliated cytology were performed every 3 months. A biopsy was performed within 24 hours and every 3 months before the end of the irrigation and 6th end, respectively, for 1 year. The material was obtained at the edge of the surgical scar and at the normal mucosa. The specimen was immediately placed in liquid nitrogen and stored at -70°C. Frozen sections were prepared and stained by the Cordell method. Detection was performed after labeling with monoclonal and polyclonal antibodies. Microscopic examinations of the muscularis, submucosa, and epithelial layer, with at least three microscopic fields of infiltrating cell types (Th/Ti, Ts/Tc, and IL-2) counted in each patient